Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avecho Biotechnology Limited ( (AU:AVE) ) has shared an announcement.
Avecho Biotechnology has completed the treatment phase for the 244 patients needed for an interim analysis of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia. The study, designed to support Australian regulatory registration and eventual over-the-counter availability, randomises patients to two CBD doses or placebo and aims to improve CBD absorption and efficacy.
Interim results, expected in late June 2026, will provide the first formal read on efficacy, determine the final trial size and guide ongoing licensing talks. Avecho has already licensed Australian commercial rights to Sandoz, securing upfront and milestone payments plus double-digit royalties, and a positive readout could de-risk the program while strengthening its position in both the domestic OTC CBD segment and the global US$5.22 billion insomnia market.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian drug delivery company that develops human and animal health products using its patented Tocopheryl Phosphate Mixture, derived from Vitamin E to enhance drug absorption. Its lead asset is a TPM-enhanced cannabidiol soft-gel capsule in Phase III development for insomnia, targeting Australia’s emerging over-the-counter CBD market and broader global sleep disorder markets.
Average Trading Volume: 9,836,848
Technical Sentiment Signal: Sell
Current Market Cap: A$45.97M
See more data about AVE stock on TipRanks’ Stock Analysis page.